Business and Significant Accounting Policies (Details 2) (K-V Pharmaceutical Company, USD $) In Millions, unless otherwise specified	1 Months Ended		12 Months Ended	21 Months Ended	24 Months Ended
	Aug. 31, 2007	May 31, 2007	Dec. 31, 2011 unit	May 15, 2009 M	May 15, 2009 Y deliverable
Sale of Evamist product
Milestone payment reimbursed			$ 1.5
Milestone payment paid			3
Evamist product
Sale of Evamist product
Upfront payment received	140	10
Number of remaining deliverables					2
Number of years to commence closing					2
Number of units of accounting			1
Revenue recognized on a pro-rata basis on sale of product				150
License to improvements remaining term (in months)				21.5
Maximum milestone payments eligible to be received			$ 30